NCT04892446 2025-05-02
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 2 Terminated
Clinical Trials
57 trialsNCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT02188368 2023-11-03
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT00464178 2022-07-20
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT03117361 2020-12-02
Trial of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
PharmaMar
Phase 2 Terminated
NCT01438177 2020-02-24
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00574236 2019-12-13
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT02102594 2019-12-03
TAVAB
Charite University, Berlin, Germany
Phase 2 Terminated
NCT00765102 2019-11-25
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Celgene
Phase 2 Terminated
NCT00416793 2019-10-31
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00920556 2019-02-27
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
GlaxoSmithKline
Phase 2 Terminated
NCT00023881 2018-11-14
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00103376 2018-11-05
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00413959 2018-09-19
VRCD
Oncology Specialists, S.C.
Phase 2 Terminated
NCT00124579 2018-08-09
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Terminated
NCT00200382 2018-08-02
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Montefiore Medical Center
Phase 2 Terminated
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT02877082 2018-04-30
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Phase 2 Terminated
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01315873 2018-02-07
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00818649 2017-12-28
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01312818 2017-12-28
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00085410 2017-07-02
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT01729338 2017-05-31
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Duke University
Phase 2 Terminated
NCT01465386 2017-04-04
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02254551 2017-02-16
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01186458 2016-10-24
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00983346 2016-07-11
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
Phase 2 Terminated
NCT01536067 2016-06-10
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01497275 2015-07-15
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Duke University
Phase 2 Terminated
NCT01062230 2015-04-06
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
University of Arkansas
Phase 2 Terminated
NCT00210392 2015-03-30
VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Terminated
NCT01078441 2015-01-12
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01653418 2014-10-15
V-BEAM
Washington University School of Medicine
Phase 2 Terminated
NCT01397591 2014-07-30
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00851552 2014-07-21
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00510887 2014-05-12
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Duke University
Phase 2 Terminated
NCT01902862 2014-04-01
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
Janssen-Cilag G.m.b.H
Phase 2 Terminated
NCT00718640 2013-10-29
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
Janssen-Ortho Inc., Canada
Phase 2 Terminated
NCT00346645 2013-02-06
A Phase II Study of VelcadeĀ® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT00040768 2013-01-16
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00128921 2012-04-26
Study of VelcadeĀ® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
University of Arkansas
Phase 2 Terminated